---
title: "Advanced Biomed Completes AI Acquisition and Leadership Transition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284946343.md"
description: "Advanced Biomed Inc. has completed the acquisition of Acellent Technologies for approximately $1.08 million in an all-stock deal. This acquisition marks a strategic shift towards AI-focused products, moving away from its legacy life sciences business. CEO Yi Lu has stepped down, and Xiaomin Chen, former CEO of Acellent, has been appointed as the new CEO. The company aims to leverage AI technologies for regulated financial markets, focusing on large language models and trustworthy AI verification systems."
datetime: "2026-05-01T22:47:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284946343.md)
  - [en](https://longbridge.com/en/news/284946343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284946343.md)
---

# Advanced Biomed Completes AI Acquisition and Leadership Transition

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Advanced Biomed Inc. ( (ADVB) ).

On April 2, 2026, Advanced Biomed Inc. agreed to acquire 100% of Acellent Technologies (Hong Kong) Co. Limited from its sole shareholder, Xiaomin Chen, in an all‑stock deal valued at approximately $1.08 million, paid through the issuance of 270,000 common shares, with the transaction completed on April 30, 2026. The acquisition and accompanying shift toward AI-focused products mark a significant change in the company’s operational direction and signal a move away from its legacy life sciences business.

In connection with this strategic pivot, Advanced Biomed and Chief Executive Officer Yi Lu agreed to a mutual separation, under which Lu received 39,999 shares as severance compensation, and he stepped down as CEO, director and chairman. The board appointed Xiaomin Chen, a veteran AI and fintech technologist and former CEO of the acquired Acellent, as the new CEO, director and chairman effective April 28, 2026, under an employment agreement providing monthly compensation of $12,000, consolidating leadership and ownership interests as the company reorients around AI for financial markets.

**More about Advanced Biomed Inc.**

Advanced Biomed Inc., historically focused on life sciences, is pivoting its primary business toward artificial intelligence development. The company is repositioning around AI technologies for regulated financial markets, leveraging capabilities in large language models and trustworthy AI verification systems aimed at precision, explainability and compliance for financial-sector clients.

**Average Trading Volume:** 484,952

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $7.3M

Learn more about ADVB stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)

## Related News & Research

- [Trillion-dollar Samsung faces a battle over who gets the AI profits](https://longbridge.com/en/news/287013238.md)
- [Jim Cramer Says Nvidia Should Stay Inside China’s AI Boom, Not Walk Away](https://longbridge.com/en/news/286804523.md)
- [2 AI Stocks That Will Still Be Dominant When Today's Hype Has Faded](https://longbridge.com/en/news/286951863.md)
- [SoundHoundAI stock analysis: Buy or sell this AI stock?](https://longbridge.com/en/news/286826155.md)
- [AI tools are 60% more likely to prefer their own resumes](https://longbridge.com/en/news/286654482.md)